Personalized treatment of lung cancer

Seminars in Oncology

Volumn 38, Issue 2, 2011, Pages 274-283

  Salgia, Ravi ^a   Hensing, Thomas ^a   Campbell, Nicholas ^a   Salama, April K ^a   Maitland, Michael ^a   Hoffman, Philip ^a   Villaflor, Victoria ^a   Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; AFATINIB; ANTINEOPLASTIC AGENT; ARQ 197; BEVACIZUMAB; CARBOPLATIN; CBL PROTEIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4 ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; HYBRID PROTEIN; K RAS PROTEIN; NAVELBINE; PACLITAXEL; PEMETREXED; PF 299804; PLACEBO; SCATTER FACTOR RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG; ZILEUTON;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CIRCULATING TUMOR CELL; DIAGNOSTIC ACCURACY; DRUG EFFICACY; FUSION GENE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOGENE K RAS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RACE; TREATMENT RESPONSE; TUMOR CELL;

DRUG RESISTANCE, NEOPLASM; GENES, RAS; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MUTATION; NEOPLASTIC CELLS, CIRCULATING; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GROWTH FACTOR;

EID: 79952924786     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.01.012     Document Type: Article

References (74)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer Statistics, 2010 CA Cancer J Clin 6 2010 277 300
2. M. Maemondo, A. Inoue, and K. Kobayashi Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
3. D. Johnson, L. Fehrenbacher, and W. Novotny Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191 (Pubitemid 41095154)
4. A. Sandler, R. Gray, and J. Brahmer Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer: an Eastern Cooperative Oncology Group trial - E4599 J Clin Oncol 23 Suppl 2005 4
5. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550 (Pubitemid 44917502)
6. A.B. Sandler, J.H. Schiller, and R. Gray Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable nonsmall-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab J Clin Oncol 27 2009 1405 1412
7. M.A. Socinski, S. Novello, and J.R. Brahmer Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer J Clin Oncol 26 2008 650 656 (Pubitemid 351264362)
8. G.V. Scagliotti, P. Parikh, and J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
9. K.N. Syrigos, J. Vansteenkiste, and P. Parikh Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed v cisplatin-gemcitabine in advanced non-small-cell lung cancer Ann Oncol 21 2010 556 561
10. T. Ciuleanu, T. Brodowicz, and C. Zielinski Maintenance pemetrexed plus best supportive care v placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 2009 1432 1440
11. J.E. Grilley-Olson, D. Hayes, and B.F. Qaqish Diagnostic reproducibility of squamous cell carcinoma in the ear of histology-directed non-small cell chemothearpy: a large prospective study J Clin Oncol 2009 27 Abstract 8008
12. B.Z. Ring, R.S. Seitz, and R.A. Beck A novel five-antibody immunohistochemical test for subclassification of lung carcinoma Mod Pathol 22 2009 1032 1043
13. E. Giovannetti, V. Mey, and S. Nannizzi Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells Mol Pharmacol 68 2005 110 118 (Pubitemid 41002949)
14. R.M. Schultz, V.J. Chen, J.R. Bewley, E.F. Roberts, C. Shih, and J.A. Dempsey Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs Semin Oncol 26 1999 68 73 (Pubitemid 29218031)
15. M.A. Socinski, E.F. Smit, and P. Lorigan Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer J Clin Oncol 27 2009 4787 4792
16. P. Ceppi, M. Volante, and S. Saviozzi Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase Cancer 107 2006 1589 1596 (Pubitemid 44546920)
17. V. Monica, G.V. Scagliotti, and P. Ceppi Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung Clin Cancer Res 15 2009 7547 7552
18. G. Scagliotti, C. Kaiser, and B. Biesma Correlations of biomarker expression and clinical outxome in a large phase III trial of pemetrexed plus cisplatin or gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer J Thorac Oncol 2 2007 S375
19. Y. Bang, E.L. Kwak, and A.T. Shaw Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) J Clin Oncol (Meeting Abstracts) 28 2010 3
20. F.R. Hirsch, M. Varella-Garcia, and P.A. Bunn Jr Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis J Clin Oncol 21 2003 3798 3807 (Pubitemid 46606235)
21. M. Ray, R. Salgia, and E.E. Vokes The role of EGFR inhibition in the treatment of non-small cell lung cancer Oncologist 14 2009 1116 1130
22. S.M. Ahmed, and R. Salgia Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer Respirology 11 2006 687 692 (Pubitemid 44581431)
23. T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139 (Pubitemid 38637993)
24. W. Pao, V. Miller, and M. Zakowski EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 2004 13306 13311 (Pubitemid 39209661)
25. M.S. Tsao, A. Sakurada, and J.C. Cutz Erlotinib in lung cancermolecular and clinical predictors of outcome N Engl J Med 353 2005 133 144 (Pubitemid 41058345)
26. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
27. D.M. Jackman, V.A. Miller, and L.-A. Cioffredi Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials Clin Cancer Res 15 2009 5267 5273
28. P.A. Janne, X.F. Wang, and M.A. Socinski Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 J Clin Oncol (Meeting Abstracts) 28 2010 7503
29. C. Yang, J. Shih, and W. Su A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2) J Clin Oncol (Meeting Abstracts) 28 2010 7521
30. M.J. Boyer, F.H. Blackhall, and K. Park Efficacy and safety of PF299804 v erlotinib (E): a global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT) J Clin Oncol (Meeting Abstracts) 28 2010 LBA7523
31. J.A. Engelman, and P.A. Jnne Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer Clin Cancer Res 14 2008 2895 2899
32. J.R. Sierra, V. Cepero, and S. Giordano Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy Mol Cancer 9 2010 75
33. T. Kosaka, Y. Yatabe, and H. Endoh Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib Clin Cancer Res 12 2006 5764 5769 (Pubitemid 44629607)
34. G.R. Oxnard, G.J. Riely, and M.H. Arcila Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI) J Clin Oncol (Meeting Abstracts) 28 2010 7520
35. R.J. Slebos, R.E. Kibbelaar, and O. Dalesio K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung N Engl J Med 323 1990 561 565 (Pubitemid 20260082)
36. C. Mascaux, N. Iannino, and B. Martin The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer 92 2005 131 139 (Pubitemid 40188446)
37. S.A. Ahrendt, P.A. Decker, and E.A. Alawi Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung Cancer 92 2001 1525 1530 (Pubitemid 32947838)
38. T. Mitsudomi, S.M. Steinberg, and H.K. Oie ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent Cancer Res 51 1991 4999 5002
39. H.H. Nelson, D.C. Christiani, E.J. Mark, J.K. Wiencke, J.C. Wain, and K.T. Kelsey Implications and prognostic value of K-ras mutation for early-stage lung cancer in women J Natl Cancer Inst 91 1999 2032 2038
40. M.S. Tsao, S. Aviel-Ronen, and K. Ding Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer J Clin Oncol 25 2007 5240 5247 (Pubitemid 350232256)
41. C. Lu, J.C. Soria, and X. Tang Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers J Clin Oncol 22 2004 4575 4583 (Pubitemid 41185125)
42. K. Suda, K. Tomizawa, and T. Mitsudomi Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation Cancer Metast Rev 29 2010 49 60
43. D.M. Jackman, V.A. Miller, and L.A. Cioffredi Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials Clin Cancer Res 15 2009 5267 5273
44. E. Van Cutsem, I. Lang, and G. D'haens KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience J Clin Oncol (Meeting Abstracts) 26 2008 2
45. K.J. O'Byrne, I. Bondarenko, and C. Barrios Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the FLEX study J Clin Oncol (Meeting Abstracts) 27 2009 8007
46. R. Pirker, J.R. Pereira, and A. Szczesna Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 2009 1525 1531
47. T.J. Lynch, T. Patel, and L. Dreisbach Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099 J Clin Oncol 28 2010 911 917
48. S. Khambata-Ford, C.T. Harbison, and L.L. Hart Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer J Clin Oncol 28 2010 918 927
49. Y.P. Mosse, A. Wood, and J.M. Maris Inhibition of ALK signaling for cancer therapy Clin Cancer Res 15 2009 5609 5614
50. H. Mano Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer Cancer Sci 99 2008 2349 2355
51. M. Soda, Y.L. Choi, and M. Enomoto Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566 (Pubitemid 47206930)
52. A.T. Shaw, B.Y. Yeap, and M. Mino-Kenudson Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 2009 4247 4253
53. J.G. Christensen, J. Burrows, and R. Salgia c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention Cancer Lett 225 2005 1 26 (Pubitemid 40732764)
54. P.C. Ma, R. Jagadeeswaran, and S. Jagadeesh Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer Cancer Res 65 2005 1479 1488 (Pubitemid 40270177)
55. E.S. Kim, and R. Salgia MET pathway as a therapeutic target J Thorac Oncol 4 2009 444 447
56. F. Cappuzzo, A. Marchetti, and M. Skokan Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients J Clin Oncol 27 2009 1667 1674
57. J.A. Engelman, K. Zejnullahu, and T. Mitsudomi MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043 (Pubitemid 46799492)
58. J.H. Schiller, W.L. Akerley, and W. Brugger Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 v erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) J Clin Oncol (Meeting Abstracts) 28 2010 LBA7502
59. O. Abidoye, M.K. Ferguson, and R. Salgia Lung carcinoma in African Americans Nat Clin Pract Oncol 4 2007 118 129 (Pubitemid 46189540)
60. X. Wu, H. Zhao, and C.I. Amos p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity J Natl Cancer Inst 94 2002 681 690 (Pubitemid 34552489)
61. S. Krishnaswamy, R. Kanteti, and J.S. Duke-Cohan Ethnic differences and functional analysis of MET mutations in lung cancer Clin Cancer Res 15 2009 5714 5723
62. P. Peschard, T.M. Fournier, and L. Lamorte Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein Mol Cell 8 2001 995 1004 (Pubitemid 34031802)
63. P. Peschard, and M. Park From Tpr-Met to Met, tumorigenesis and tubes Oncogene 26 2007 1276 1285 (Pubitemid 46328462)
64. C. Tan, S. Krishnaswamy, and S. Nandi CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases PLoS One 5 2010 e8972
65. H. Wolff, N.K. Saukkone, S. Anttila, A. Karjalainen, H. Vainio, and A. Ristimaki Expression of cyclooxygenase-2 in human lung carcinoma Cancer Res 58 1998 4997 5001 (Pubitemid 28521147)
66. F. Khuri, H. Wu, and J. Lee Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer Clin Cancer Res 7 2001 861 867 (Pubitemid 32708722)
67. J.L. Masferrer, K.M. Leahy, and A.T. Koki Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors Cancer Res 60 2000 1306 1311 (Pubitemid 30151999)
68. M.J. Edelman, D. Watson, and X. Wang Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapyCancer and Leukemia Group B trial 30203 J Clin Oncol 26 2008 848 855 (Pubitemid 351398075)
69. H.-Y. Chen, S.-L. Yu, and C.-H. Chen A five-gene signature and clinical outcome in nonsmall-cell lung cancer N Engl J Med 356 2007 11 20 (Pubitemid 46041749)
70. M. Skrzypski, E. Jassem, and M. Taron Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung Clin Cancer Res 14 2008 4794 4799
71. W.J. Allard, J. Matera, and M.C. Miller Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases Clin Cancer Res 10 2004 6897 6904 (Pubitemid 39383039)
72. S. Nagrath, L.V. Sequist, and S. Maheswaran Isolation of rare circulating tumour cells in cancer patients by microchip technology Nature 450 2007 1235 1239
73. S. Maheswaran, L.V. Sequist, and S. Nagrath Detection of mutations in EGFR in circulating lung-cancer cells N Engl J Med 359 2008 366 377
74. A.C. Hoffmann, T. Gauler, A. Parr, W.E. Eberhardt, and M.H. Schuler Use of ERCC1 expression levels in circulating tumor cells to predict response to platinum-based chemotherapy in patients with non-small cell lung cancer J Clin Oncol (Meeting Abstracts) 28 2010 7512